Esophageal Cancer Clinical Trial
Official title:
Rehabilitative Strategies Following Oesophageal Cancer
The ReStOre trial is a multi-disciplinary intervention of exercise, diet and education for patients who have completed treatment for oesophageal cancer. The intervention aims to improve quality of life and functional performance following oesophageal cancer and assist patients to return to normal activity during the early survivorship phase. The 12-week intervention will involve structured exercise training, individual dietary advice and multi-disciplinary education sessions addressing a range of survivorship needs.
The principal study proposed in this work will be composed of two phases. Phase I will
consist of a longitudinal analysis, tracking the progression of cachexia and associated
dysmetabolic state throughout treatment for oesophageal cancer (OC) and examining the impact
of this decline on measures of physical functioning. A total of 88 newly-diagnosed OC
patients will be recruited for Phase I. In Phase II, participants from Phase I will be
re-assessed and if deemed suitable, will be enrolled onto a multidisciplinary team
rehabilitation programme aimed at improving functional status. This rehabilitation programme
will take the form of a randomised controlled trial (RCT) and will be based on the
well-established cardiac rehabilitation programme model. It is anticipated that approximately
50% of participants enrolled onto Phase I will be suitable for progression to Phase II.
Outcomes The primary outcome across both Phase I and Phase II is functional capacity.
Secondary outcomes including inflammatory status, energy metabolism and nutritional status
will be measured as appropriate during the study. All outcomes are discussed in detail
elsewhere.
Phase I: Longitudinal Study Examining the impact of progressive cachexia, dysmetabolism and
cancer treatment on functional capacity in OC patients
Phase I will be designed as a longitudinal analysis, commencing at the time of diagnosis,
tracking the progression of cachexia and associated dysmetabolic state, incorporating
inflammatory profiles, energy metabolism (oxidative phosphorylation and glycolysis) and gut
hormones, throughout treatment for OC and examining the impact of this decline on measures of
physical functioning. Assessments will be completed at diagnosis (T0), cycle 2 chemotherapy
(T1), cycle 3 chemotherapy (T2), pre-oesophagectomy (T3), post-oesophagectomy (T4), 4-weeks
post-surgery (T5) and six months post-surgery (T6). All assessments will be completed during
the same day as routine out-patient appointments thereby reducing the burden on participants.
Furthermore, blood samples will be taken during routine clinical sampling and CT scans will
be completed as part of routine medical care.
Phase II: Randomised Controlled Trial Can rehabilitation following curative treatment for OC
optimise health-related functional outcomes?
Phase II will examine the effect of a 12-week rehabilitation programme, incorporating a
walking intervention, individualised nutritional advice and education session, on functional
status following curative treatment for OC. Following completion of Phase I and medical
clearance to progress to Phase II, participants will be randomised 1:1 to either the
intervention group or a control group. The control group will not receive the intervention
however following completion of final assessments, participants will be offered an individual
exercise and dietary session with the research physiotherapist and dietitian. During the
intervention period, participants in the control group will continue to receive routine
medical care.
The primary outcome for the multidisciplinary rehabilitation programme will be a change in
functional capacity as measured by aerobic capacity. Secondary measures of functional
capacity will include a stair climbing test, hand grip and physical activity. Body
composition will also be measured by bio impedance analysis. The secondary outcomes that will
be assessed are nutritional status, dietary quality and healthy related quality of life
(QOL). Inflammatory profiles, measures of energy metabolism and gut hormones are unlikely to
be influenced by the proposed rehabilitative intervention and therefore will not be measured.
Assessments will be completed at, programme completion and three months post programme
completion. Assessments take place at the Welcome Trust-HRB Clinical Research Facility St.
James's Hospital. The rehabilitation programme will consist of three main components; 1.
Exercise session, 2. Dietary sessions and 3. Education sessions. The intervention outlined
below is devised based best evidence, pilot data and clinical expertise. The design final
design will be informed form the results of the feasibility study and from needs identified
in Phase I.
Exercise Sessions The exercise component of the rehabilitation programme will take the form
of a 12 week supervised and home-based walking intervention. A walking intervention was
chosen as walking is the most common form of exercise completed by adults nationally and
worldwide, it is safe and feasible for deconditioned cohorts and represents a functionally
meaningful activity. The feasibility of implementing a similar programme in cancer survivors
has been previous established.
Group walking sessions will be supervised twice weekly during the first four weeks of the
programme to re-introduce exercise to participant's lives in a safe and structured manner. As
the programme progresses the frequency of supervised sessions will decrease to increase
participants independence with the protocol. In the absence of guidance on appropriate
exercise prescription in cancer cohorts, exercise intensity will be prescribed in accordance
with the American College of Sports Medicine (ACSM) guidelines for exercise in deconditioned
populations (28). Initially, activity will be prescribed at a light intensity and will
progress during the programme to a moderate aerobic intensity. The proposed starting
intensity is based on pilot data from the investigators institute suggesting that aerobic
fitness levels are either 'poor' or 'very poor' in the early post-treatment phase.
Participants will wear Polar Heart Rate monitors during all sessions to ensure compliance
with the exercise prescribed. The goal at programme completion will be participation in 30
minutes of moderate intensity activity five days per week, as per the ACSM physical activity
guidelines.
Nutrition Sessions Nutrition sessions will be delivered during week 1, week 2 and then
fortnightly on a one to one basis. Weight and circumferential measures will be recorded at
each session and dietary intake will be assessed as described previously.
The education delivered in the nutrition sessions will be individualised to participants
needs. There is limited knowledge of the specific nutritional needs of oesophageal cancer
survivors. Based on experience at this centre, the investigators anticipate that a
heterogeneous mix of dietary issues requiring intervention will present in this cohort. These
include persistent weight loss, anorexia, gastrointestinal disturbance and altered bowel
habit. In addition, participants may require specific dietary advice to reduce the risk of
other diseases e.g. cardio-protective dietary advice. Furthermore, the increase in physical
activity by participants throughout the intervention will require dietary monitoring and
advice to avoid inappropriate negative energy balance.
The feasibility study will assist in identifying specific nutritional issues facing
oesophageal cancer survivors and help inform content and delivery of the nutrition education
sessions. The target for participants is optimal dietary intake in line with the WCRF
guidelines for cancer survivors. Supporting literature detailing prescriptive dietary advice
will be developed and provided to participants.
Education Sessions Education sessions will be delivered weekly during weeks 1-4 and
fortnightly thereafter by a range of members of the multidisciplinary team. As per the
cardiac rehabilitation model, education sessions will talk place after the exercise session
and cool-down, to monitor participant recovery following exercise. Education topics covered
by the physiotherapist will include advice regarding physical activity guidelines,
discouraging sedentary behaviour and overcoming barriers to physical activity. The dietitian
will discuss dietary management of gastrointestinal symptoms and will also educate
participants on healthy eating for cancer survivors as per World Cancer Research Fund,
including practical advice and strategies to achieve dietary goals. Participants will be
encouraged to highlight topics that may be of particular concern to them for discussion. As
per the cardiac rehabilitation model, such topics may be covered by members of the
multi-disciplinary team including the surgeon, gastrointestinal nurse, occupational therapist
or social worker. Education sessions will take place at the Welcome Trust-HRB Clinical
Research Facility St. James's Hospital.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|
||
Not yet recruiting |
NCT05542680 -
Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer
|
N/A | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Completed |
NCT00003864 -
Docetaxel Plus Carboplatin in Treating Patients With Advanced Cancer of the Esophagus
|
Phase 2 | |
Recruiting |
NCT05491616 -
Nivolumab During Active Surveillance After Neoadjuvant Chemoradiation for Esophageal Cancer: SANO-3 Study
|
Phase 2 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT00199849 -
NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
|
Phase 1 | |
Completed |
NCT03756597 -
PAN-study: Pan-Cancer Early Detection Study (PAN)
|
||
Completed |
NCT00400114 -
Sutent Following Chemotherapy, Radiation and Surgery For Resectable Esophageal Cancer
|
Phase 2 | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Recruiting |
NCT04615806 -
The Value of Lymph Node Dissection of Indocyanine Green-guided Near-infrared Fluorescent Imaging in Esophagectomy
|
N/A | |
Active, not recruiting |
NCT04566367 -
Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer
|
N/A | |
Active, not recruiting |
NCT03962179 -
Feasibility and Efficacy of a Combination of a SEMS and Vacuum Wound Treatment (VACStent)
|
N/A | |
Terminated |
NCT01446874 -
Prevention of Post-operative Pneumonia (POPP)
|
Phase 2/Phase 3 | |
Completed |
NCT03468634 -
Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy
|
N/A | |
Active, not recruiting |
NCT02869217 -
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT01404156 -
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
|
Phase 2/Phase 3 |